Synovus Financial Corp Acquires New Shares in United Therapeutics Co. (NASDAQ:UTHR)

Synovus Financial Corp acquired a new stake in United Therapeutics Co. (NASDAQ:UTHRGet Rating) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 900 shares of the biotechnology company’s stock, valued at approximately $212,000.

Other hedge funds have also recently bought and sold shares of the company. Charter Oak Capital Management LLC purchased a new position in United Therapeutics in the 2nd quarter valued at approximately $25,000. Cullen Frost Bankers Inc. acquired a new stake in United Therapeutics during the 2nd quarter valued at $26,000. Hallmark Capital Management Inc. acquired a new stake in United Therapeutics during the 2nd quarter valued at $33,000. MCF Advisors LLC acquired a new stake in United Therapeutics during the 1st quarter valued at $34,000. Finally, Sandy Cove Advisors LLC acquired a new stake in United Therapeutics during the 1st quarter valued at $58,000. 95.57% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $265.59 on Tuesday. United Therapeutics Co. has a twelve month low of $158.38 and a twelve month high of $270.61. The stock has a market capitalization of $12.11 billion, a P/E ratio of 18.07, a PEG ratio of 1.77 and a beta of 0.59. The company has a current ratio of 9.68, a quick ratio of 9.39 and a debt-to-equity ratio of 0.18. The business’s fifty day moving average price is $228.55 and its 200 day moving average price is $224.37.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $203.34, for a total value of $1,220,040.00. Following the transaction, the executive vice president now owns 36,397 shares in the company, valued at $7,400,965.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $203.34, for a total value of $1,220,040.00. Following the transaction, the executive vice president now owns 36,397 shares in the company, valued at $7,400,965.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Louis W. Sullivan sold 710 shares of United Therapeutics stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $211.56, for a total value of $150,207.60. Following the completion of the transaction, the director now owns 12,180 shares in the company, valued at approximately $2,576,800.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 66,230 shares of company stock worth $16,335,737. 12.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on UTHR shares. HC Wainwright increased their target price on United Therapeutics from $255.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, November 3rd. Morgan Stanley raised their price objective on United Therapeutics from $288.00 to $322.00 and gave the stock an “overweight” rating in a report on Thursday, November 3rd. Bank of America restated an “underperform” rating on shares of United Therapeutics in a report on Tuesday, September 20th. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $240.00 to $265.00 and gave the stock an “overweight” rating in a report on Thursday, November 3rd. Finally, StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $282.75.

United Therapeutics Company Profile

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Stories

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHRGet Rating).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.